WaferGen Bio Story Overview

WGBS -- USA Stock  

USD 6.90  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for WaferGen Bio. But even though we do not provide professional-grade financial sentiment analysis on WaferGen Bio systems, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for WaferGen Bio. See also WaferGen Bio Hype Analysis, WaferGen Bio Correlation and WaferGen Bio Performance.
Exercise or conversion by Joel Kanter of 1250 shares of WaferGen Bio subject to Rule 16b-3
Filed transaction by Wafergen Biosystems Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

WaferGen Bio systems Inc insider trading alert for exercise of restricted stock units by Joel Kanter, the corporate stakeholder, on October 2, 2017. This event was filed by Wafergen Biosystems Inc with SEC on 2010-12-20. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for WaferGen Bio

over a week ago at www.macroaxis.com 
WaferGen Bio exotic insider transaction detected
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Unconventional Insider trading
over a week ago at www.macroaxis.com 
Acquisition by Coradini Robert of 20000 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over two weeks ago at www.macroaxis.com 
Purchase by Shivji Alnoor of 1500 shares of WaferGen Bio
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. General open market or private purchase of non-derivative or derivative security
over three weeks ago at www.macroaxis.com 
Exercise or conversion by Hariri Robert J of 1250 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over a month ago at www.macroaxis.com 
Purchase by Shivji Alnoor of 2870 shares of WaferGen Bio
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. General open market or private purchase of non-derivative or derivative security
over a month ago at www.macroaxis.com 
WaferGen Bio exotic insider transaction detected
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Unconventional Insider trading
over a month ago at http://healthcaretrends24.com 
Single cell Analysis Market Size, Share, Regional Trend, Leading Players Updates, Future Growth, Business Pros...
news
Healthcare TrendsFull coverage
over two months ago at http://truthtoday24.com 
Global Single-cell Analysis Market Industry 2025 by Worldwide Market Size, Key Vendors, Growth Rate, Drivers ....
news
The Truth TodayFull coverage
over two months ago at www.macroaxis.com 
Exercise or conversion by Coradini Robert of 1250 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over two months ago at www.macroaxis.com 
Acquisition by Shivji Alnoor of 150000 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over three months ago at www.macroaxis.com 
WaferGen Bio exotic insider transaction detected
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Unconventional Insider trading
over six months ago at www.macroaxis.com 
Acquisition by Joel Kanter of 20000 shares of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
over six months ago at www.macroaxis.com 
Disposition of 58469 shares by Ivan Trifunovich of WaferGen Bio subject to Rule 16b-3
Macroaxis News
Filed transaction by Wafergen Biosystems Inc director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Price to Book

Price to Book Comparative Analysis
WaferGen Bio is currently under evaluation in price to book category among related companies. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.

Peers

WaferGen Bio Related Equities
IIVI  2.51 %   
0%
100.0%
COHR  1.31 %   
0%
52.0%
ORBK  1.18 %   
0%
47.0%
IART  0.43 %   
0%
17.0%
MKSI  0.30 %   
0%
11.0%
ABAX  0.01 %   
1.0%
0%
FTV  0.03 %   
1.0%
0%
CGNX  0.18 %   
7.0%
0%
TER  0.47 %   
18.0%
0%
BRKR  1.56 %   
62.0%
0%
See also WaferGen Bio Hype Analysis, WaferGen Bio Correlation and WaferGen Bio Performance. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">